Inclisiran in advanced chronic kidney disease (stage G4–G5 non-dialysis): sustained LDL-C reduction and favorable safety profile at 1-year follow-up in a real-world case series - Top-Institutions - MDSpire

Inclisiran in advanced chronic kidney disease (stage G4–G5 non-dialysis): sustained LDL-C reduction and favorable safety profile at 1-year follow-up in a real-world case series

  • By

  • Avinash Chandu Nanwani

  • Jose Carlos De la Flor Merino

  • Elena Jiménez Mayor

  • Juan Daniel Díaz García

  • Celia Rodríguez Tudero

  • Arturo Villalobos Navarro

  • Esperanza Moral Berrio

  • Adriana Puente García

  • Jesus Hernández Vaquero

  • June 22, 2026

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Hospital Gómez Ulla
    Hospital Gómez Ulla

    Madrid, Spain

    Key Differentiators

    • Nephrology

  • #2

    Jena University Hospital
    Jena University Hospital

    Jena, Germany

    Key Differentiators

    • Cardiology
    • Nephrology

Original Source(s)

Inclisiran in advanced chronic kidney disease (stage G4–G5 non-dialysis): sustained LDL-C reduction and favorable safety profile at 1-year follow-up in a real-world case series

  • by Avinash Chandu Nanwani, Jose Carlos De la Flor Merino, Elena Jiménez Mayor, Juan Daniel Díaz García, Celia Rodríguez Tudero, Arturo Villalobos Navarro, Esperanza Moral Berrio, Adriana Puente García, Jesus Hernández Vaquero

  • June 22, 2026

Related Content

Subclinical primary aldosteronism and major adverse cardiovascular events: evidence for a continuum of renin-independent aldosterone excess and a proposal for early detection

MRI-derived IVIM-modelled diffusion-weighted imaging does not predict clinical outcomes in fontan-associated liver disease: to monitor or not to monitor the liver?

The effects of combined endurance and resistance exercise training in heart failure: a meta-analysis